Brain Diseases  >>  LMTX (hydromethylthionine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LMTX (hydromethylthionine) / TauRx
NCT01689246 / 2012-002866-11: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Checkmark CTAD 2016
Dec 2016 - Dec 2016: CTAD 2016
Checkmark
Jul 2016 - Jul 2016: 
Completed
3
891
US, Canada, Europe, RoW
TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo
TauRx Therapeutics Ltd
Alzheimer's Disease
11/15
11/15
NCT01626378 / 2011-005529-34: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Checkmark
Sep 2016 - Sep 2016: 
Checkmark
Jul 2016 - Jul 2016: 
Completed
3
220
US, Canada, Europe, RoW
TRx0237, Placebo
TauRx Therapeutics Ltd
Behavioral Variant Frontotemporal Dementia (bvFTD)
02/16
02/16
NCT01689233 / 2012-002847-28: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Checkmark
Nov 2017 - Nov 2017: 
Checkmark CTAD 2016
Dec 2016 - Dec 2016: CTAD 2016
Checkmark
More
Completed
3
800
US, Canada, Europe, RoW
TRx0237 200 mg/day, Placebo
TauRx Therapeutics Ltd
Alzheimer's Disease
05/16
05/16

Download Options